Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-067 in advanced solid malignancies
NCT04787042Phase 2Recruiting
- Sponsor
- Simcha Therapeutics
- Start
- Aug 2021
- Primary completion
- Jun 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of vevoctadekin in solid tumor, melanoma, renal cell carcinoma (RCC) and 4 more (4 arms), sponsored by Simcha Therapeutics. Primary endpoints: Maximum Tolerated Dose at Day 29, Overall Safety and Tolerability at Day 29 and 2 more. Started Aug 2021; status: recruiting.
02
Drugs
vevoctadekin
03
Conditions
solid tumormelanomarenal cell carcinoma (RCC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04787042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787042.